PERJETA Prescribing Information KADCYLA Prescribing Information PHESGO Prescribing Information

HERConnection

a support program made for you

What you need, when you need it—information and resources to help you stay on track and stay on top of your HER2+ breast cancer treatment journey.

TAKE THE FIRST STEP

What is HERConnection?

HERConnection is a free support program designed specifically for people with HER2+ breast cancer taking Genentech medicines, providing information and resources that can help educate and empower you throughout your treatment journey.

Remember, your doctor and your healthcare team are your primary sources of information. Only they can give you medical advice about your disease and treatment.
 

Quick Links

How it works

Sign up for free

FAQs

three small yellow dots used as a design element to separate content

Tools and resources to support your treatment journey*

Illustration of pink treatment journal with an orange pencil

Treatment journal

Keep track of your appointments and notes

Illustration of pink water bottle filled halfway with orange liquid

Water bottle

Help with hydration during treatment

Illustration of pink cookbook with an orange fork and knife crossed on the cover

Eating Well Through Cancer

Cookbook made specifically for patients and caregivers

three small yellow dots used as a design element to separate content

Information designed with you in mind*

Illustration of the letter i for information

Treatment education

Facts about the medicine you are taking and what to expect during treatment

Illustration of a cartoon person with their hands up and a heart on their chest

Support for a healthy lifestyle

Tips for healthy eating, staying active, and emotional well-being during and after treatment

Illustration of a dollar sign inside a circle

Financial assistance

Detailed guidance around financial assistance options you may be eligible for

Illustration of a hand holding a heart

Access to support groups

Connect with various support groups and resources that you can tap into

*Be aware that materials and information may differ depending on your course of treatment.

How HERConnection works

Information and resources—tailored to what you need, when you need them

When you sign up, you will receive emails and packages in the mail over the course of your treatment journey.

Since everyone’s journey is a little different, we do our best to deliver only the materials and information that make the most sense for you depending on your course of treatment.

Just answer a few questions to get started >

Illustration of a woman opening a box

Sign up for HERConnection for free

We value your privacy.

Your personal information is only being collected so we can provide you with relevant information and resources based on your treatment journey. Please see additional details on Genentech’s Privacy Policy at the bottom of the page.

All fields marked with an asterisk (*) are required.

About your treatment

 

Thank you for your interest.

The HERConnection support program is only available to people receiving treatment with a Genentech medication.

If you're interested in learning more about early HER2+ treatment options, click here.

My doctor is giving me this treatment for (select one):*

QUICK TIP:

Early breast cancer means that the cancer has not spread to other parts of the body, outside the breast and lymph nodes under the arm.

Metastatic breast cancer means that the cancer has spread to other parts of the body, outside the breast and lymph nodes under the arm.

My doctor is giving me this treatment for (select one):*

QUICK TIP:

Early breast cancer means that the cancer has not spread to other parts of the body, outside the breast and lymph nodes under the arm.

Metastatic breast cancer means that the cancer has spread to other parts of the body, outside the breast and lymph nodes under the arm.

My doctor is giving me this treatment for (select one):*

QUICK TIP:

Early breast cancer means that the cancer has not spread to other parts of the body, outside the breast and lymph nodes under the arm.

Metastatic breast cancer means that the cancer has spread to other parts of the body, outside the breast and lymph nodes under the arm.

To ensure we’re sending you the right materials at the right time—and not sending anything you don’t need—please tell us:

Which of the following most closely describes your current treatment?*
Have you had surgery already?*
Did you receive HER2+ breast cancer treatment before surgery?*

To ensure we’re sending you the right materials at the right time—and not sending anything you don’t need—please tell us:

To ensure we’re sending you the right materials at the right time—and not sending anything you don’t need—please tell us:

Which of the following most closely describes your current treatment?*
Have you had surgery already?*
Did you receive HER2+ breast cancer treatment before surgery?*
Did your doctor switch you from PERJETA + Herceptin-based therapy?*
Did your doctor switch you from PERJETA + Herceptin-based therapy?*

Contact Information

How is this used?

  • We ask for your contact information so that we can provide you with relevant information and resources for your treatment journey. Some of this will be sent via email, and some will be sent in the mail.

You're all set.

Illustration of a pink checkmark

Thank you for signing up for HERConnection. We’ve received your information and look forward to connecting with you.

Stay tuned and keep an eye on your inbox—support for your treatment journey is on its way!

Remember, your doctor and your healthcare team should be your primary source of information. Only they can give you medical advice about your disease and treatment. Genentech’s intent is to provide information only to patients and caregivers in the United States or its territories.

We Value Your Privacy

By providing your information, you agree to allow Genentech and its agents to collect the information provided and to be contacted by Genentech and its agents in the future regarding Genentech Products and related disease education. Furthermore, you are agreeing that Genentech and its agents may contact you by phone, email, or mail, and that such electronic or other written communications may include information regarding your health within them. Genentech will not sell, rent, or otherwise distribute your name and any personally identifiable information outside of Genentech and its agents. Genentech will only use your information in accordance with the Genentech Privacy Policy.

Contact Us

If you have any questions about the Genentech Privacy Policy or the information practices of our sites, you may contact us

Illustration of a pink at sign

by e-mail at [email protected]

Illustration of a pink envelope

or by mail at:

Genentech, Inc.
Attn: Privacy Office
1 DNA Way
South San Francisco, CA 94080

Frequently Asked Questions

The Genentech Patient Resource Center can help answer questions and connect you to an appropriate Genentech patient support service.

1 (877) GENENTECH (436-3683) | Monday-Friday, 6am-5pm PST

This is not meant to replace the advice of your healthcare team.

HERConnection is designed specifically for people with HER2+ breast cancer who are taking Genentech medicines. That means you can sign up if you’re currently taking PERJETA + Herceptin-based therapy, KADCYLA, or PHESGO for HER2+ breast cancer.

If you are a caregiver to someone taking one of these medicines, you are welcome to sign up on their behalf, but keep in mind that you will be receiving information and resources geared toward your loved one.

Unfortunately, HERConnection is only available to people who are taking Genentech medicines like PERJETA + Herceptin-based therapy, KADCYLA, or PHESGO.

If you have HER2+ breast cancer, you can talk to your healthcare team about your treatment options and if one of these medicines might be right for you.

When you sign up, you’ll receive a number of emails over the course of your treatment journey. Each email will contain information, tips, and guidance relevant to that particular stage in your breast cancer treatment experience.

You’ll also receive one or more packages in the mail with more helpful information, as well as free tools that you can use to support a healthy lifestyle. These may include a treatment journal, water bottle, and cookbook designed specifically for cancer patients and caregivers.

Remember that everyone’s journey is a little different. So it’s important that you tell us a bit about your treatment plan so we can deliver the materials and information that make the most sense for you.

Absolutely not! HERConnection is 100% free. If you have HER2+ breast cancer and are taking a Genentech medicine, you are eligible to sign up for free to get information and resources to help guide you throughout your treatment journey.

HERConnection does not provide financial assistance.

However, there are a number of other resources that Genentech offers to help you afford your medicine, no matter what type of health insurance you have.

You can explore financial resources here or call the Genentech Patient Resource Center at (877) GENENTECH/(877) 436-3683 to learn more.

Of course you can! But it’s helpful to fill in a start date. The more information you give us, the better we can guide and support you. We are committed to delivering information, tips, and resources that are timely and that align with your treatment experience, when you need it.

If you’re not sure of your start date, you can ask your healthcare team, or make a rough guess.

Yes. It’s easy to opt out. Just click on the “Unsubscribe” button in any of the emails you receive. Or you can call the Genentech Patient Resource Center at (877) GENENTECH/(877) 436-3683.

Your personal information is only being collected so we can provide you with relevant information and resources based on your treatment journey.

By providing your information, you agree to allow Genentech and its agents to collect the information provided and to be contacted by Genentech and its agents in the future regarding Genentech Products and related disease education. Furthermore, you are agreeing that Genentech and its agents may contact you by phone, email, or mail, and that such electronic or other written communications may include information regarding your health within them.

Genentech will not sell, rent, or otherwise distribute your name and any personally identifiable information outside of Genentech and its agents. Genentech will only use your information in accordance with the Genentech Privacy Policy.

Important Safety Information/Uses

PERJETA® (pertuzumab)

KADCYLA® (ado-trastuzumab emtansine)

PHESGO® (pertuzumab/trastuzumab/hyaluronidase-zzxf)

What does PERJETA treat?

PERJETA® (pertuzumab) is a prescription medicine approved for use in combination with Herceptin® (trastuzumab) and chemotherapy for:

  • use prior to surgery (neoadjuvant treatment) in people with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (tumor is greater than 2 cm in diameter or node-positive). PERJETA should be used as part of a complete treatment regimen for early breast cancer. 
  • use after surgery (adjuvant treatment) in people with HER2-positive early breast cancer that has a high likelihood of coming back.

PERJETA® (pertuzumab) is a prescription medicine approved for use in combination with Herceptin® (trastuzumab) and docetaxel in people who have HER2-positive breast cancer that has spread to different parts of the body (metastatic) and who have not received anti-HER2 therapy or chemotherapy for metastatic breast cancer.

What should I know about side effects with PERJETA?

  • Not all people have serious side effects; however, side effects with PERJETA therapy are common. It is important to know what side effects may happen and what symptoms you should watch for
  • Your doctor may stop treatment if serious side effects happen. Be sure to contact your healthcare team right away if you have questions or are worried about any side effects

What are the most serious side effects of PERJETA?

PERJETA may cause heart problems, including those without symptoms (such as reduced heart function) and those with symptoms (such as congestive heart failure).

  • Your doctor may run tests to monitor your heart function before and during treatment with PERJETA
  • Based on test results, your doctor may hold or discontinue treatment with PERJETA
  • Contact a health care professional immediately for any of the following: new onset or worsening shortness of breath, cough, swelling of the ankles/legs, swelling of the face, palpitations, weight gain of more than 5 pounds in 24 hours, dizziness or loss of consciousness

Receiving PERJETA during pregnancy can result in the death of an unborn baby and birth defects.

  • Birth control should be used while receiving PERJETA and for 7 months after your last dose of PERJETA. If you are a mother who is breastfeeding, you should talk with your doctor about either stopping breastfeeding or stopping PERJETA
  • If you think you may be pregnant, you should contact your healthcare provider immediately
  • If you are exposed to PERJETA during pregnancy, or become pregnant while receiving PERJETA or within 7 months following the last dose of PERJETA in combination with Herceptin, you are encouraged to report PERJETA exposure to Genentech at 1-888-835-2555

What are other possible serious side effects?

  • PERJETA should not be used in patients who are allergic to pertuzumab or to any of the ingredients in PERJETA
  • Infusion-related reactions: PERJETA is a medicine that is delivered into a vein through a needle. PERJETA has been associated with infusion-related reactions, some fatal. The most common infusion-related reactions when receiving PERJETA, Herceptin, and docetaxel were feeling tired, abnormal or altered taste, allergic reactions, muscle pain, and vomiting. The most common infusion-related reactions when receiving PERJETA alone were fever, chills, feeling tired, headache, weakness, allergic reactions, and vomiting
  • Severe allergic reactions: Some people receiving PERJETA may have severe allergic reactions, called hypersensitivity reactions or anaphylaxis, which may happen quickly and may affect many areas of the body. Severe allergic reactions, some fatal, have been observed in patients treated with PERJETA

What are the most common side effects?

The most common side effects of PERJETA when given with Herceptin and chemotherapy as part of an early breast cancer regimen before surgery are:

  • Constipation
  • Damage to the nerves (numbness, tingling, pain in hands/feet) 
  • Diarrhea
  • Feeling tired 
  • Hair loss 
  • Headache
  • Low levels of red blood cells 
  • Low levels of white blood cells with or without fever 
  • Low platelet count 
  • Mouth blisters or sores 
  • Nausea
  • Pain in the muscles 
  • Vomiting
  • Weakness 

Side effects may vary based on chemotherapy regimen.

The most common side effects of PERJETA when given with Herceptin and chemotherapy as part of an early breast cancer regimen after surgery are:

  • Diarrhea 
  • Nausea 
  • Hair Loss 
  • Feeling tired 
  • Damage to the nerves (numbness, tingling, pain in hands/feet)
  • Vomiting

The most common side effects of PERJETA when given with Herceptin and docetaxel for treatment of breast cancer that has spread to other parts of the body (metastatic) are:

  • Diarrhea
  • Hair loss
  • Low levels of white blood cells with or without fever
  • Nausea
  • Feeling tired
  • Rash
  • Damage to the nerves (numbness, tingling, pain in hands/feet)

You are encouraged to report side effects to Genentech and the FDA. You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.

Talk to a healthcare professional for more information about the benefits and risks of PERJETA.

Please see full Prescribing Information for additional Important Safety Information, including most serious side effects.

If you cannot afford your medication, visit genentech-access.com/patient for financial assistance information.

Who is KADCYLA for?

Early Breast Cancer

KADCYLA is a prescription medicine used as an adjuvant (after surgery) treatment for HER2-positive early breast cancer when the patient has taken neoadjuvant (before surgery) treatment including a taxane and trastuzumab (Herceptin®) and there is cancer remaining in the tissue removed during surgery.

Patients are selected for therapy based on an FDA-approved test for KADCYLA.

Metastatic Breast Cancer

KADCYLA is a prescription medicine used to treat HER2-positive breast cancer that has spread to other parts of the body (metastatic breast cancer) after prior treatment with trastuzumab (Herceptin®) and a taxane. Prior treatment could have been for the initial treatment of breast cancer or for the treatment of cancer that had spread to other parts of the body.

Patients are selected for therapy based on an FDA-approved test for KADCYLA.

What is the most Important Safety Information I should know about KADCYLA?

Liver problems

  • KADCYLA may cause severe liver problems that can be life-threatening. Symptoms of liver problems may include vomiting, nausea, eating disorder (anorexia), yellowing of the skin (jaundice), stomach pain, dark urine, or itching

Heart problems

  • KADCYLA may cause heart problems, including those without symptoms (such as reduced heart function) and those with symptoms (such as congestive heart failure). Symptoms may include swelling of the ankles or legs, shortness of breath, cough, rapid weight gain of more than 5 pounds in 24 hours, dizziness or loss of consciousness, or irregular heartbeat

Pregnancy

  • Receiving KADCYLA during pregnancy can result in the death of an unborn baby and birth defects. Birth control should be used while you receive KADCYLA and for 7 months after your last dose of KADCYLA
  • If you think you may be pregnant, you should contact your healthcare provider immediately
  • If you are exposed to KADCYLA during pregnancy or if you become pregnant within 7 months following your last dose of KADCYLA, you are encouraged to report KADCYLA exposure to Genentech by calling 1-888-835-2555
  • If you are a male patient with a female partner that could become pregnant, birth control should be used during treatment and for 4 months following your last dose of KADCYLA
  • You should not breastfeed during treatment and for 7 months after the last dose of KADCYLA

Contact your doctor right away if you experience symptoms associated with these side effects.

What are the additional possible serious side effects of KADCYLA?

Lung problems

  • KADCYLA may cause lung problems, including inflammation of the lung tissue, which can be life-threatening. Signs of lung problems may include trouble breathing, cough, tiredness, and fluid in the lungs

Infusion-related reactions

  • Symptoms of an infusion-related reaction may include one or more of the following: the skin getting hot or red (flushing), chills, fever, trouble breathing, low blood pressure, wheezing, tightening of the muscles in the chest around the airways, or a fast heartbeat. Your doctor will monitor you for infusion-related reactions

Serious bleeding

  • KADCYLA can cause life-threatening bleeding. Taking KADCYLA with other medications used to thin your blood (antiplatelet) or prevent blood clots (anticoagulation) can increase your risk of bleeding. Your doctor should provide additional monitoring if you are taking one of these other drugs while on KADCYLA. Even when blood thinners are not also being taken, life-threatening bleeding may occur with KADCYLA

Low platelet count

  • Low platelet count may happen during treatment with KADCYLA. Platelets help your blood to clot. Signs of low platelets may include easy bruising, bleeding, and prolonged bleeding from cuts. In mild cases there may not be any symptoms

Nerve damage

  • Symptoms may include numbness and tingling, burning or sharp pain, sensitivity to touch, lack of coordination, muscle weakness, or loss of muscle function. Your doctor will monitor you for symptoms of nerve damage

Skin reactions around the infusion site

  • KADCYLA may leak from the vein or needle and cause reactions such as redness, tenderness, skin irritation, or pain or swelling at the infusion site. If this happens, it is more likely to happen within 24 hours of the infusion

What are the most common side effects of KADCYLA?

The most common side effects in people taking KADCYLA for early breast cancer are:

  • Tiredness
  • Nausea
  • Liver problems
  • Pain that affects the bones, muscles, ligaments, and tendons
  • Bleeding
  • Low platelet count
  • Headache
  • Weakness, numbness, and pain in the hands and feet
  • Joint pain

The most common side effects seen in people taking KADCYLA for metastatic breast cancer are:

  • Tiredness
  • Nausea
  • Pain that affects the bones, muscles, ligaments, and tendons
  • Bleeding
  • Low platelet count
  • Headache
  • Liver problems
  • Constipation
  • Nosebleeds

You are encouraged to report side effects to Genentech and the FDA. You may contact Genentech by calling 1-888-835-2555. You may contact the FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088. 

Talk to a healthcare professional for more information about the benefits and risks of KADCYLA.

Please see full Prescribing Information for Important Safety Information, including most serious side effects.

If you cannot afford your medication, visit genentech-access.com/patient for financial assistance information.

What does PHESGO treat?

PHESGO® (pertuzumab, trastuzumab, and hyaluronidase-zzxf) is a prescription medicine approved for use in combination with chemotherapy for:

  • use prior to surgery (neoadjuvant treatment) in adults with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (tumor is greater than 2 cm in diameter or node-positive). PHESGO should be used as part of a complete treatment regimen for early breast cancer. 
  • use after surgery (adjuvant treatment) in adults with HER2-positive early breast cancer that has a high likelihood of coming back.

PHESGO is a prescription medicine approved for use in combination with docetaxel in adults who have HER2-positive breast cancer that has spread to different parts of the body (metastatic) and who have not received anti-HER2 therapy or chemotherapy for metastatic breast cancer.

What should I know about side effects with PHESGO?

  • Not all people have serious side effects; however, side effects with PHESGO therapy are common. It is important to know what side effects may happen and what symptoms you should watch for
  • Your doctor may stop treatment if serious side effects happen. Be sure to contact your healthcare team right away if you have questions or are worried about any side effects

What are the most serious side effects of PHESGO?

PHESGO may cause heart problems, including those without symptoms (such as reduced heart function) and those with symptoms (such as congestive heart failure).

  • The risk for and seriousness of these heart problems are highest in people who received both PHESGO and a certain type of chemotherapy (anthracycline)
  • Your doctor will check for signs of heart problems before, during, and after treatment with PHESGO. Based on test results, your doctor may hold or discontinue treatment with PHESGO
  • Contact a healthcare professional immediately for any of the following: new onset or worsening shortness of breath, cough, swelling of the ankles/legs, swelling of the face, palpitations, weight gain of more than 5 pounds in 24 hours, dizziness or loss of consciousness

Receiving PHESGO during pregnancy can result in the death of an unborn baby and birth defects.

  • Birth control should be used while receiving PHESGO and for 7 months after your last dose of PHESGO. If you are a mother who is breastfeeding, you should talk with your doctor about either stopping breastfeeding or stopping PHESGO
  • If you think you may be pregnant, you should contact your healthcare provider immediately
  • If you are exposed to PHESGO during pregnancy, or become pregnant while receiving PHESGO or within 7 months following the last dose of PHESGO, you are encouraged to report PHESGO exposure to Genentech at 1-888-835-2555

PHESGO may cause serious lung problems.

  • Your doctor may check for signs of lung problems including:
    • Severe shortness of breath
    • Fluid in or around the lungs
    • Weakening of the valve between the heart and the lungs
    • Not enough oxygen in the body
    • Swelling of the lungs
    • Scarring of the lungs

Who should not receive PHESGO?

  • PHESGO should not be used in patients who are allergic to pertuzumab, trastuzumab, hyaluronidase, or to any of the ingredients in PHESGO

What are other possible serious side effects?

  • PHESGO may worsen low white blood cell counts caused by chemotherapy: Low white blood cell counts can be life threatening and were seen more often in patients receiving Herceptin® (trastuzumab) plus chemotherapy than in patients receiving chemotherapy alone. Your doctor may check for signs of low white blood cell counts when he or she examines you
  • PHESGO may cause administration-related reactions: PHESGO is given as an injection. The active ingredients in PHESGO have been associated with severe administration reactions, including hypersensitivity or anaphylaxis, which can be fatal. Talk to your doctor if you feel any symptoms. The most common symptoms include dizziness, nausea, chills, fever, vomiting, diarrhea, hives, swelling of the skin, breathing problems, or chest pain

What are the most common side effects?

The most common side effects of PHESGO when given with chemotherapy as part of an early breast cancer regimen are:

  • Hair Loss
  • Nausea
  • Diarrhea
  • Low levels of red blood cells
  • Weakness

The most common side effects of PHESGO when given with docetaxel for treatment of breast cancer that has spread to other parts of the body (metastatic) are:

  • Diarrhea
  • Hair loss
  • Low levels of white blood cells with or without fever
  • Nausea
  • Feeling tired
  • Rash
  • Damage to the nerves (numbness, tingling, pain in hands/feet)

You are encouraged to report side effects to Genentech and the FDA. You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.

Talk to a healthcare professional for more information about the benefits and risks of PHESGO.

Please see full Prescribing Information for additional Important Safety Information, including most serious side effects.

If you cannot afford your medication, visit genentech-access.com/patient for financial assistance information.